MGVS begins phase I trials of blood vessel therapy

MGVS - MultiGene Vascular Systems Ltd. has begun Phase I human clinical trials of its MultiGeneGraf cell therapy for growing blood vessels. The company is due to obtain US Food and Drug Administration (FDA) approval to begin Phase I trials of its second treatment, MultiGeneAngio, for the prevention of blockages in prosthetic blood vessels.

Although MGVS is an early-stage company, market sources consider it one of the more interesting Israeli companies in its field. Its flagship product, MultiGeneGraft, is designed to foster the development of new blood vessels that bypass blocked veins and arteries in the limbs. The process involves taking a sample of the patient’s vein and breaking it down into its constituent parts: muscle cells and endothelial cells (smooth-walled cells that cover the surface of blood vessels, enabling regular flow of blood, while preventing of clots on arterial walls). The cells are treated in a proprietary compound developed by MGVS that, when injected into the muscle and endothelial cells fosters their healthy growth even if the original cells are aged and slightly diseased.

 

''Globes''